SVB Leerink analyst Andrew Berens maintains AstraZeneca (NASDAQ:AZN) with a Outperform and raises the price target from $70 to $75.
Citi Trends Sees Q1 EPS $0.15-$0.40, Sees FY22 EPS $4.05-$4.60
Guidance
Fiscal 2022 is difficult to predict as the Company is up against last year's largest government stimulus and the lifting of COVID-19 restrictions that led to a surge in consumer demand, particularly in
